Compare CCSI & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | IRWD |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.4M | 526.7M |
| IPO Year | 2022 | 2009 |
| Metric | CCSI | IRWD |
|---|---|---|
| Price | $26.40 | $4.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $37.50 | $7.67 |
| AVG Volume (30 Days) | 107.2K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | ★ 4.35 | 0.15 |
| Revenue | ★ $349,696,000.00 | $298,276,000.00 |
| Revenue This Year | $3.33 | $57.95 |
| Revenue Next Year | $2.70 | $4.39 |
| P/E Ratio | ★ $5.85 | $29.13 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $17.84 | $0.55 |
| 52 Week High | $31.67 | $5.78 |
| Indicator | CCSI | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 66.15 |
| Support Level | $25.07 | $3.07 |
| Resistance Level | $26.62 | $5.67 |
| Average True Range (ATR) | 1.04 | 0.23 |
| MACD | 0.21 | 0.13 |
| Stochastic Oscillator | 94.63 | 91.00 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.